Scientific Resources

AllArticleNewsTechnical Articles

News

10/10/2024

Ciliatech selected to showcase Intercil® Uveal Spacer, novel glaucoma surgical device, at Eyecelerator

Major event for advancing innovation in eye care gives Ciliatech first-time opportunity to show US ophthalmic audiences potential of treating open and narrow angle glaucoma in supraciliary space with single device.

News

09/05/2024

Ciliatech presents 36-month follow-up data on novel CID implant, Intercil® Uveal Spacer, for treating glaucoma

Ciliatech today announces it will present the combined results of a 36-month follow-up of its SAFARI I & II clinical trials on its groundbreaking Intercil® Uveal Spacer, a Cilioscleral Interpositioning Device (CID), at the Ophthalmology Futures European Forum, taking place today.

Article

05/14/2024

Cilioscleral Interposition Device for Intraocular Pressure Lowering

A new device grows the glaucoma arsenal while potentially preventing endothelial cell loss and inflammation. By: Philippe Sourdille, MD - GLAUCOMA PHYSICIAN

News

04/24/2024

Ciliatech’s glaucoma implant CID receives favorable opinion on treating both open and narrow angle forms of disease

First independent observations, presented by Dr. Leon Au, leading consultant ophthalmology and eye surgeon, during ICGS 2024 in Abu Dhabi, underscore CID’s strong potential as treatment option for glaucoma.

News

12/05/2023

Ciliatech releases new design of glaucoma surgical device CID, following patent reinforcement

Second-generation CID (Cilioscleral Interpositioning Device) makes cilioscleral surgical procedure, which leaves anterior chamber of eye untouched, less invasive and easier to perform.

Technical Articles

10/23/2023

Alleviating the burden of PACG treatment

Primary angle-closure glaucoma (PACG) represents a significant cause of blindness, affecting more than 17 million people worldwide. Moreover, the currently available treatment options for the management PACG remain relatively limited. The cilioscleral inter-positioning device is a novel minimally invasive implant designed to increase uveoscleral outflow without entering the chamber. This unique approach to lower IOP represents a new, efficient, and safe surgical option to reduce intraocular pressure for patients with PACG.

News

09/07/2023

Preliminary one-year study results on treating open and narrow angle glaucoma with CID

Ciliatech presents preliminary one-year study results on treating open and narrow angle glaucoma with CID at Ophthalmology Futures Symposium.

News

08/09/2023

Ophthalmology Times Europe

At the World Glaucoma Congress (WGC) in Rome, Italy this summer, Ciliatech presented preliminary results of the second 2-year postoperative clinical trial (SAFARI Ⅱ) on its Cilioscleral Interposition Device (CID).

Technical Articles

07/19/2023

How the cilioscleral approach fits in with other glaucoma surgical techniques

Glaucoma is a group of progressive, neurodegenerative eye diseases associated with irreversible optic neuropathy followed by visual-field impairment. Epidemiological estimates suggest that the most common form,

News

06/28/2023

Two-year post-operative results on new cilio-scleral surgical approach for treating glaucoma

Results from second CID (Cilio-scleral Interposition Device) study confirm sustained decrease in intraocular pressure (IOP), while preserving anterior chamber of eye